Long noncoding RNA CPS1-IT1 is recently recognized as a
tumor suppressor in several
cancers. Here, we investigate the role of CPS1-IT1 in human
melanoma. Presently, our study reveals the low expression of CPS1-IT1 in human
melanoma tissues and cell lines, which is significantly associated with
metastasis and
tumor stage. Besides, the potential of CPS1-IT1 as a prognosis-predictor is strongly indicated. Functionally, CPS1-IT1 overexpression inhibits cell migration, invasion, epithelial-mesenchymal transition, and angiogenesis in
melanoma cells. CYR61, an
angiogenic factor that participates in
tumor metastasis as well as a recognized oncogene in
melanoma, is shown to be confined under CPS1-IT1 overexpression in
melanoma cells. Furthermore, enforced expression of Cyr61 in CPS1-IT1-silenced
melanoma cells dramatically normalized the
protein level of Cyr61 and that of its downstream targets
vascular endothelial growth factor and
matrix metalloproteinase-9, as well as the repressive effect of CPS1-IT1 overexpression on
melanoma cell
metastasis. BRG1, a core component of SWI/SNF complex, is implied to interact with both CPS1-IT1 and Cyr61 in
melanoma cells. Moreover, CPS1-IT1 negatively regulates Cyr61 expression by blocking the binding of BRG1 to Cyr61 promoter. Jointly, CPS1-IT1 controls
melanoma metastasis through impairing Cyr61 expression via competitively binding with BRG1, uncovering a novel potential therapeutic and prognostic
biomarker for patients with
melanoma.